Q Therapeutics is pioneering a novel approach to treating central nervous system (CNS) diseases through the development of human cell-based therapies that focus on glial cells. These non-neuronal cells play a crucial role in supporting and maintaining neuronal health. The company's primary therapeutic candidate, Q-Cells®, consists of human glial progenitor cells that can differentiate into specialized glial cells, specifically astrocytes and oligodendrocytes. Pre-clinical studies have demonstrated that Q-Cells® can replicate, migrate to sites of injury, and differentiate effectively, leading to improved neuronal function and survival without toxicity. This innovative therapy aims to address debilitating conditions such as transverse myelitis and amyotrophic lateral sclerosis (ALS), for which Q Therapeutics has received FDA clearance to initiate clinical trials.

The unique characteristics of Q-Cells® set them apart in the field of cellular therapies. Unlike traditional stem cell therapies, Q-Cells® are allogeneic, meaning they are not harvested from the patient but are instead prepared as an off-the-shelf product. They are isolated from brain tissue in their natural state, ensuring no genetic manipulation occurs. Each vial contains millions of glial progenitor cells capable of multiplying and differentiating into the necessary glial cell types. Q-Cells® have shown promising results in pre-clinical models, demonstrating their ability to migrate to damaged areas, produce myelin, and enhance motor function and survival in conditions like ALS and multiple sclerosis. With a strong intellectual property position and ongoing preparations for clinical trials, Q Therapeutics is positioned to make significant advancements in the treatment of neurodegenerative diseases.

United States

Q Therapeutics is a biotechnology company based out of 417 S Wakara Way, Salt Lake City, UT, United States.

Q Therapeutics

Company Details